Stocks Health care CAMP
NASDAQ · Health careCamp4 Therapeutics Corp (CAMP)
Camp4 Therapeutics Corp brought in $5.3M of revenue over the twelve months to September 30, 2026, up 39.9% from a year earlier. It posted a net loss of $121.1M. In fiscal 2025 capital spending exceeded operating cash flow by $29.8M. At September 30, 2026 it held $124.5M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 5, 2026.
Key facts about Camp4 Therapeutics Corp
- Net worth
- Camp4 Therapeutics Corp has a market value (market cap) of $294.3M at the latest share price, and shareholders' equity of $107.1M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $3.5M (+436.5% year on year), with a net loss of $80.4M. Over the 12 months to September 30, 2026: revenue $5.3M, net loss $121.1M.
- Cash flow
- In fiscal 2025 operations used $29.6M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 5, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Camp4 Therapeutics Corp's next report was expected around November 5, 2026 and is not on file with the SEC yet.
What Camp4 Therapeutics Corp does
Camp4 Therapeutics Corp is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker CAMP.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $3.5M | -$80.4M | -$2.65 | -$29.8M |
| 2024 | $652K | -$51.8M | -$11.04 | -$46M |
| 2024 | $350K | -$49.3M | -$124.80 | -$44.8M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where CAMP ranks in Health care
Latest SEC filings
What Camp4 Therapeutics Corp has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 5, 2026Quarterly report 10-Q · period to September 30, 2026Revenue rose 139% to $1.9M versus the same quarter last year; diluted EPS -$0.37 versus -$0.55.
- November 5, 2026Exhibits 8-K
- November 5, 2026Passive stake changed SCHEDULE 13G/A
- September 28, 2026
- August 31, 2026Activist stake changed SCHEDULE 13D/A
- August 19, 2026Activist stake changed SCHEDULE 13D/A
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 13, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 19% to $1.8M versus the same quarter last year; diluted EPS -$0.58 versus -$0.62.
- August 13, 2026
- August 10, 2026Passive stake (5% or more) SCHEDULE 13G
Insider trades
What the people running Camp4 Therapeutics Corp did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders bought $39.6K and sold $2.5M worth of shares in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| August 31, 2026 | Gold KellyChief Financial Officer | Boughtindirect | 10,000 | $39.6K |
| August 27, 2026 | Schwab Andrew J.Director | Soldindirect | 400,000 | $1.6M |
| August 24, 2026 | Schwab Andrew J.Director | Soldindirect | 10 | $45 |
| August 21, 2026 | Schwab Andrew J.Director | Soldindirect | 32,018 | $144.1K |
| August 20, 2026 | Schwab Andrew J.Director | Soldindirect | 114,700 | $520.7K |
| August 19, 2026 | Schwab Andrew J.Director | Soldindirect | 45,147 | $214.9K |
| August 19, 2026 | Tardiff DanielChief Scientific Officer | Sold | 1,738 | $8.3K |
| August 3, 2026 | Mandel-Brehm JoshChief Executive Officer, Director | Bought | 6,551 | $10.8K |
Who owns CAMP
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Janus Henderson Group PLC13G, passive | 12.2% | January 8, 2026 |
| Coastlands Capital LP13G, passive with 4 related filers | 9.99% | December 11, 2025 |
| Andrew J. Schwab13D, may seek influence with 7 related filers | 9.9% | August 31, 2026 |
| Fmr LLC13G, passive with 1 related filers | 9.5% | February 5, 2026 |
| Vivo Opportunity Fund Holdings, L.P.13G, passive with 3 related filers | 7.4% | February 13, 2026 |
| Amir Nashat13D, may seek influence with 7 related filers | 6.3% | August 19, 2026 |
| Trails Edge Capital Partners, LP13G, passive with 2 related filers | 6% | August 10, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 61 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Jupiter Topco LLC | 6,307,636 | new |
| 5AM Venture Management, LLC | 5,869,091 | 0 |
| Fmr LLC | 4,904,339 | -29,093 |
| Vivo Capital, LLC | 4,246,568 | 0 |
| Balyasny Asset Management L.P. | 2,575,724 | -56,713 |
| a16z Capital Management, L.L.C. | 2,125,339 | 0 |
| Adage Capital Partners GP, L.L.C. | 1,960,784 | 0 |
| Trails Edge Capital Partners, LP | 1,932,937 | -6,626 |
| BlackRock, Inc. | 1,644,134 | +1,187,763 |
| Vanguard Capital Management LLC | 1,533,489 | -1,279 |
| Enavate Sciences GP, LLC | 1,425,541 | -765,379 |
| Stonepine Capital Management, LLC | 1,389,622 | 0 |
| HarbourVest Partners LLC | 1,271,948 | 0 |
| Geode Capital Management, LLC | 795,651 | +412,830 |
| SummitTX Capital, L.P. | 725,160 | +385,639 |
| Silverarc Capital Management, LLC | 653,594 | 0 |
| State Street Corp | 362,300 | +215,400 |
| Northern Trust Corp | 248,673 | +178,007 |
| Goldman Sachs Group Inc | 241,393 | +163,048 |
| Vanguard Fiduciary Trust Co | 226,074 | +31,061 |
Insiders
5 insiders reported holding 2,601,665 shares in total, about $12.2M at the last price.
| Holder | Shares |
|---|---|
| Schwab Andrew J.Director | 2,033,2702,033,270 held indirectly |
| Mandel-Brehm JoshChief Executive Officer, Director | 284,968 |
| Young Richard ADirector | 186,388 |
| Gold KellyChief Financial Officer | 84,42810,000 held indirectly |
| Maricich YuriChief Medical Officer | 12,611 |
Questions about CAMP
What does Camp4 Therapeutics Corp do?
Camp4 Therapeutics Corp is a company in the Health care sector, listed on NASDAQ as CAMP. Its shares trade on NASDAQ under the ticker CAMP.
What is Camp4 Therapeutics Corp's net worth?
Camp4 Therapeutics Corp has a market value (market cap) of $294.3M at the latest share price, and shareholders' equity of $107.1M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Camp4 Therapeutics Corp profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $121.1M on revenue of $5.3M.
How much revenue does Camp4 Therapeutics Corp make?
Over the twelve months to September 30, 2026 Camp4 Therapeutics Corp reported revenue of $5.3M. That is 39.9% more than a year earlier.
When did Camp4 Therapeutics Corp last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 5, 2026. It covers the period to September 30, 2026.
When is Camp4 Therapeutics Corp's next earnings report?
Camp4 Therapeutics Corp's next report was expected around November 5, 2026 and is not on file with the SEC yet.
Similar companies
Compare CAMP with
Follow CAMP
Get an email when Camp4 Therapeutics Corp files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Camp4 Therapeutics Corp tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.